Kane Biotech Inc. (TSXV:KNE)
Canada flag Canada · Delayed Price · Currency is CAD
0.0300
+0.0050 (20.00%)
Aug 28, 2026, 2:46 PM EST

Kane Biotech Financials Overview

Millions CAD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.040.432.080.150.161.61
Revenue Growth
-97.91%-79.44%1296.75%-4.95%-90.25%19.84%
Gross Profit
-0-00.870.110.110.57
Operating Income
-2.63-2.61-3.72-3.35-3.46-4.82
Net Income
-2.7-2.726.1-5.03-3.89-4.6
Earnings Per Share
-0.02-0.020.05-0.04-0.03-0.04
EPS Growth
------

Revenue by Segment

Fiscal YearFY 2025FY 2024FY 2023
Period EndingDec '25 Dec '24 Dec '23
Animal Health
0.412.492.78
Human Health
0.020.680.04
Total
0.433.162.82

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.850.90.360.751.11.15
Total Debt
1.962.32.189.266.864.72
Net Cash (Debt)
-1.11-1.4-1.82-8.51-5.76-3.57
Net Cash Growth
------
Net Cash Per Share
-0.01-0.01-0.01-0.07-0.05-0.03

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-2.5-3.26-4.11-2.08-3.04-2.29
Capital Expenditures
--0-0.02-0.01-0.01-0.19
Free Cash Flow
-2.5-3.26-4.14-2.09-3.05-2.48
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-0.04%-0.15%41.91%73.48%71.48%35.36%
Operating Margin
-6794.22%-609.87%-178.66%-2248.93%-2206.05%-299.63%
Pretax Margin
-7238.09%-661.24%-214.88%-3062.39%-2565.92%-301.65%
Profit Margin
-6980.02%-636.00%293.05%-3379.05%-2481.86%-286.39%
FCF Margin
-6453.52%-761.99%-198.77%-1403.79%-1947.70%-153.99%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--2.48---
PS Ratio
158.9916.987.2770.8071.6811.07